Is Stevanato Group S.p.A. (STVN) A Good Stock To Buy Now?

Looker_Studio/Shutterstock.com

Stevanato Group S.p.A. engages successful the design, production, and organisation of products and processes to supply solutions for biopharma and healthcare industries successful Europe, the Middle East, Africa and internationally. STVN delivered a beardown Q4 performance, importantly beating statement expectations and reinforcing the company’s underlying maturation trajectory.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Reported gross grew 5% versus statement of 0.8%, portion integrated maturation reached 7% compared to debased single-digit expectations, driven by robust execution successful its high-value solutions segment. Growth was led by Biopharmaceutical and Diagnostic Solutions, with High-Value Solutions expanding 31% twelvemonth implicit year, offsetting continued weakness successful engineering.

Importantly, Stevanato Group disclosed that GLP-1 related gross represented astir 19–20% of full income and grew implicit 50%, reducing anterior marketplace fears of excessive vulnerability to oral GLP-1 disruption. Management further guided GLP-1 revenues to mid-teens maturation successful 2026, implying sustained request alternatively than deterioration. Based connected this, non-GLP operations are expected to turn astir 7%, underscoring a much balanced and diversified maturation illustration than antecedently assumed.

The institution guided 2026 integrated maturation of 9% astatine midpoint, which appears blimpish fixed humanities underestimation patterns and Q4 outperformance. Engineering remains a laggard but is progressively immaterial comparative to accelerating high-value segments. Capital expenditure of €280 million, oregon astir 21% of sales, is mostly growth-oriented, with 89% allocated to enlargement supporting semipermanent HVS request crossed Fishers and Latina facilities.

While near-term escaped currency travel remains subdued, Stevanato Group’s dependable capableness build-out implies structurally higher aboriginal net powerfulness and an estimated mid-single-digit escaped currency travel output connected normalized levels. With improving margins, beardown biologics demand, and reduced GLP-1 overhang, Stevanato Group is positioned for sustained compounding driven by durable high-value healthcare packaging enactment going guardant with confidence.